Carbidopa-levodopa (CD-LD) is the mainstay of treatment for Parkinson's disease (PD), yet most patients with advanced PD develop motor fluctuations with time when treated with CD-LD. Development of longer-acting CD-LD formulations is a major goal for reducing ... ...

请注册登录后继续浏览